Special Issue

Advances in Treatment of Leukemia

Message from the Guest Editor

Leukemia is a heterogenous cancer of blood-forming cells, including the bone marrow and the lymphatic system. It could be classified as myelocytic or lymphocytic based on the cell of origin. However, novel therapeutic agents are lacking for leukemia treatment because of its diverse pathogenesis. Bioengineering technologies such as CAR-T, antibody–drug conjugates (ADC), cancer vaccines, and nuclear acid drugs have been developed for the treatment of leukemia during the past few decades. These bioengineering technologies utilize the unique properties of biomacromolecule or immune cells and could specifically deliver drugs into leukemia cells or induce immune response, resulting in leukemia cell death. Compared with traditional chemotherapy drugs, bioengineering drugs have exhibited better biocompatibility and are becoming a promising area for leukemia treatment. This Special Issue on “Advances in Treatment of Leukemia” focuses on original research papers and comprehensive reviews which investigate multiscale novel bioengineering technologies for effective leukemia treatment.

Guest Editor

Dr. Hua Naranmandura

Department of Therapeutics & Toxicology, School of Medicine and Public Health, Zhejiang University, Hangzhou 310058, China

Deadline for manuscript submissions

closed (31 December 2023)

Bioengineering

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 5.3
Indexed in PubMed

mdpi.com/si/165464

Bioengineering
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
bioengineering@mdpi.com

mdpi.com/journal/bioengineering

Bioengineering

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 5.3
Indexed in PubMed

mdpi.com/journal/bioengineering

About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie
Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, Inspec, and other databases.

Journal Rank:

JCR - Q2 (Engineering, Biomedical) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.2 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.

MDPI